Serious adverse events (Figure 6)
Serious adverse events were evaluated based on the following three
outcomes: the number of patients experiencing a serious adverse event,
the number of serious adverse events related to the trial regimen, and
the number of serious adverse events leading to trial discontinuation.
Six out of 7 studies [5,10,13-17] reported the
aforementioned outcomes, and the pooled analysis revealed that the
number of patients experiencing serious adverse events was marginally
lower in the Finerenone group compared to the placebo group (RR = 0.95
[0.92, 0.97] p < 0.0001; I2 = 0%). Similarly, the risk of
treatment discontinuation due to serious adverse events was marginally
lower in the Finerenone group compared to the placebo group (RR = 0.94
[0.83, 1.07] p= 0.38; I2= 0%), whereas risk of serious adverse
events related to trial regimen was higher in patients treated with
Finerenone (RR = 1.36 [1.13, 1.64] p = 0.001; I2= 0%).